A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma

Interferon-α in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial

(2010) Robert J. Amato et al.   ANTI-CANCER DRUGS

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Interferon in chronic myeloid leukaemia: past and future

(2009) François Guilhot et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317

(2009) Michael S. Gordon et al.   JOURNAL OF CLINICAL ONCOLOGY

Activated Akt Prevents Antitumor Activity of Gefitinib in Renal Cancer Cells

(2009) Kenji Kuroda et al.   UROLOGY

Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma

(2008) Darren R. Feldman et al.   Clinical Genitourinary Cancer

Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial

(2008) Alain Ravaud et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY